Case Report
Acquired von Willebrand Disease Associated with Monoclonal Gammopathy of Unknown Significance
Table 1
Lab tests done during presentation, treatment, and a month after treatment.
| Lab test | Presentation | During treatment (3 days) | 1 month after treatment | Reference range |
| INR | 1.1 | N/A | 1.1 | 0.9–1.1 | PTT (sec) | 48 | N/A | 34.9 | 23–34 s | Factor VIII activity (%) | 12 | 33 | 114 | 50–160% | Factor IX activity (%) | 166 | N/A | N/A | 60–150% | Factor XI activity | 98 | N/A | N/A | 50–150% | Factor XII activity | 54 | N/A | N/A | 50–150% | vWF antigen (%) | 6 | 10 | 95 | 60–150% | Ristocetin cofactor assay (%) | < 20 | < 20 | 81 | 50–160% | vWF multimer analysis | Normal | N/A | N/A | Normal multimeric distribution | Bethesda assay | 0 | N/A | N/A | 0 |
|
|
INR: international normalized ratio; PTT: partial thromboplastin time; vWF: von Willebrand factor; N/A: not available.
|